This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Janssen Pharmaceutica Nv. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Thomas Ronald A Quinten: Innovator in Prostate Cancer Treatment
Introduction
Thomas Ronald A Quinten is a notable inventor based in Zeveneken, Belgium. He has made significant contributions to the field of medicine, particularly in the treatment of prostate cancer. His innovative approach combines various pharmaceutical compounds to enhance treatment efficacy.
Latest Patents
Quinten holds a patent for the treatment of prostate cancer using a combination of abiraterone acetate, niraparib tosylate monohydrate, and prednisone. The patent details methods of treatment that utilize both free-dose and fixed-dose combinations of these compounds, aiming to improve patient outcomes in prostate cancer therapy.
Career Highlights
Quinten is associated with Janssen Pharmaceutica NV, a leading pharmaceutical company known for its commitment to developing innovative healthcare solutions. His work at Janssen has allowed him to focus on groundbreaking research and development in oncology.
Collaborations
Throughout his career, Quinten has collaborated with esteemed colleagues, including Urbain Alfons C Delaet and Philip Erna H Heyns. These collaborations have fostered a productive environment for innovation and have contributed to advancements in cancer treatment.
Conclusion
Thomas Ronald A Quinten's contributions to prostate cancer treatment exemplify the impact of innovative thinking in medicine. His work continues to inspire advancements in therapeutic strategies for cancer patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile